Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

4 Aug 2020

Abstract excerpt

Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is responsible for the direct repair of the main TMZ-induced toxic DNA adduct, the O6-Methylguanine lesion. MGMT promoter hypermethylation is currently the only known biomarker...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32753598
DOI: 10.1038/s41467-020-17717-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomasPMID 32753598Read ↗

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomasSemantic proximity Read ↗

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastomaSemantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

A Comprehensive Review of miRNAs and Their Epigenetic Effects in GlioblastomaSemantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma ChemotherapySemantic proximity Read ↗

Epigenetic modification and characterization of the <i>MGMT</i> promoter region using CRISPRoff in glioblastoma cellsSemantic proximity Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.Semantic proximity Read ↗

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant gliomaSemantic proximity Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.